Table 4.

ROC analysis of biomarker combination in Japanese cohort

Case	n	Ctrl	n	BAG4+IL6ST+VWF+CD44*+EGFR*
				AUC	95%CI	Sens	95%CI
I	114	All ctrls	386	0.79	0.74–0.85	62.3%	0.54–0.71
II	155	All ctrls	386	0.85	0.81–0.89	71.6%	0.63–0.79
III	147	All ctrls	386	0.88	0.85–0.92	77.6%	0.68–0.85
IV	98	All ctrls	386	0.90	0.86–0.95	81.6%	0.73–0.89
All cancer	514	All ctrls	386	0.86	0.83–0.88	73.0%	0.68–0.78
All cancer	514	Normal	168	0.84	0.81–0.87	70.0%	0.62–0.75
All cancer	514	Polyps	159	0.87	0.85–0.90	76.5%	0.72–0.81
All cancer	514	Colitis	59	0.87	0.84–0.90	73.3%	0.66–0.80

^*EGFR and CD44's SLeA and -X information added to the 5-protein panel. Coefficients were calculated for All cancer vs All ctrls. All ctrls include normal, polyps and colitis samples.

AUC: area under the curve, BAG4, BAG family molecular chaperone regulator 4; EGFR, epidermal growth factor receptor; IL6ST, interleukin-6 receptor subunit beta; ROC, receiver operating characteristic; Sens., Sens: sensitivity at 90% specificity; VWF, von Willebrand factor.